Gamida Cell Ltd (NASDAQ:GMDA) Sees Significant Decline in Short Interest

Gamida Cell Ltd (NASDAQ:GMDA) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,200 shares, a decrease of 84.0% from the December 31st total of 7,500 shares. Based on an average daily trading volume, of 37,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

Gamida Cell stock opened at $4.64 on Monday. The firm has a 50 day simple moving average of $4.62 and a 200-day simple moving average of $4.41. Gamida Cell has a 1-year low of $2.93 and a 1-year high of $15.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.61 and a quick ratio of 7.60. The stock has a market cap of $112.39 million, a price-to-earnings ratio of -0.44 and a beta of 1.64.

Gamida Cell (NASDAQ:GMDA) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.07. Equities analysts expect that Gamida Cell will post -1.12 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its position in shares of Gamida Cell by 4.6% during the 3rd quarter. Millennium Management LLC now owns 69,077 shares of the company’s stock worth $299,000 after purchasing an additional 3,017 shares during the period. Phoenix Holdings Ltd. purchased a new position in shares of Gamida Cell during the 3rd quarter worth approximately $121,000. Finally, Royal Bank of Canada purchased a new position in shares of Gamida Cell during the 2nd quarter worth approximately $71,000. 23.87% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on GMDA. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of Gamida Cell in a research note on Tuesday, December 10th. Zacks Investment Research raised shares of Gamida Cell from a “sell” rating to a “hold” rating in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Gamida Cell presently has an average rating of “Buy” and a consensus target price of $14.25.

About Gamida Cell

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Featured Story: Penny Stocks, What You Need To Know

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with's FREE daily email newsletter.